Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StratMedMINOCA
NCT05198791Phase 2Recruiting
- Sponsor
- NHS Golden Jubilee
- Start
- Feb 2022
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myocardial infarction with nonobstructive coronary arteries (MINOCA) and Myocardial injury comparing Eplerenone with Standard of care (2 arms). Primary endpoint: N-terminal pro b-type natriuretic peptide at 6 months. Started Feb 2022; status: recruiting.
02
Drugs
eplerenone
03
Conditions
myocardial infarction with nonobstructive coronary arteries (MINOCA)Myocardial injury
Beyond the preview
Go deeper on NCT05198791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198791.